Zai Lab (STU:1ZLB) Total Liabilities: €375.2 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1ZLB Zai Lab Ltd STU:1ZLB
68 GF Score
Price €1.68
GF Value €2.48
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Zai Lab Total Liabilities?

Zai Lab STU:1ZLB -0.59% 68 Total Liabilities is €375.2 Mil as of Mar. 2026. GuruFocus rates STU:1ZLB with a GF Score™ of 68/100 and a GF Value™ of €2.48 (Possible Value Trap). The stock has 7 warning signs investors should review.

Zai Lab's Total Liabilities for the quarter that ended in Mar. 2026 was €375.2 Mil.

Zai Lab's quarterly Total Liabilities increased from Sep. 2025 (€339.94 Mil) to Dec. 2025 (€390.18 Mil) but then declined from Dec. 2025 (€390.18 Mil) to Mar. 2026 (€375.20 Mil).

Zai Lab's annual Total Liabilities increased from Dec. 2023 (€220.24 Mil) to Dec. 2024 (€329.34 Mil) and increased from Dec. 2024 (€329.34 Mil) to Dec. 2025 (€390.18 Mil).

Zai Lab Total Liabilities Historical Data

* Premium members only.

The historical data trend for Zai Lab's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zai Lab Total Liabilities Chart

Zai Lab Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 203.55 164.77 220.24 329.34 390.18

Zai Lab Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 335.38 322.84 339.94 390.18 375.20
STU:1ZLB
68GF Score
Zai Lab Ltd STU:1ZLB
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zai Lab Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Zai Lab's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=355.406+(11.431+-2.8421709430404E-14
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+23.342+0+0)
=390.2

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1001.216-611.037
=390.2

Zai Lab's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=339.929+(10.473+0.035000000000039
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+24.762+0+0)
=375.2

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=947.813-572.614
=375.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €375.2 Mil mean?
Zai Lab (STU:1ZLB) has a Total Liabilities of €375.2 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Zai Lab and its competitors.
Is Zai Lab's Total Liabilities too high?
Zai Lab's current Total Liabilities is €375.2 Mil. Overall, Zai Lab has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's Total Liabilities compare to STOK and ADMA?
Zai Lab's Total Liabilities of €375.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Zai Lab and its competitors. Zai Lab's current Total Liabilities is €375.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (STU:1ZLB) is currently considered Possible Value Trap. The stock's GF Value™ is €2.48, compared to a current price of €1.68 — trading 32.3% below its estimated fair value. The current Total Liabilities is €375.2 Mil. Zai Lab's overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Zai Lab (STU:1ZLB), the current Total Liabilities is €375.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zai Lab (STU:1ZLB) Overvalued in 2026?

Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued. The current stock price of €1.68 is trading 32.3% below its estimated GF Value™ of €2.48. GuruFocus considers Zai Lab to be Possible Value Trap.

Key valuation signals for STU:1ZLB:

  • Total Liabilities: €375.2 Mil
  • GF Value™: €2.48 vs. price of €1.68 (32.3% below fair value)
  • GF Score™: 68/100 with 7 warning signs

No single metric tells the full story. See the STU:1ZLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zai Lab Business Description

Other Exchanges ZLAB:USA09688:Hong Kong
Address 899 Halei Road, Building B, Pudong, Shanghai, CHN, 201203
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
68GF Score

Get the complete analysis for STU:1ZLB

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.68
Price
€2.48
GF Value